Evidence map›Paper›PMID 35956334›Full record

Trial reportNutrients2022

Efficacy and Safety of Omija (

Da-Som Kim, Hyang-Im Baek, Ki-Chan Ha, Youn-Soo Cha, Soo-Jung Park

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Comparative Analysis ofMolecules (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Da-Som KimHealthcare Claims & Management Incorporation, Jeonju 54858, Korea.
Hyang-Im BaekHealthcare Claims & Management Incorporation, Jeonju 54858, Korea.ORCID 0000-0002-2829-4499
Ki-Chan HaHealthcare Claims & Management Incorporation, Jeonju 54858, Korea.
Youn-Soo ChaDepartments of Food Science & Human Nutrition, Jeonbuk National University, Jeonju 54896, Korea.
Soo-Jung ParkDepartment of Sasang Constitutional Medicine, College of Korean Medicine, Woosuk University, Jeonju 55338, Korea.ORCID 0000-0001-8191-4290
Woosuk University · KRJeonbuk National University · KRKorea Food Research Institute · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A previous animal study demonstrated that the administration of Omija extract and soybean mixture (OSM) improved glycemic control in the type 2 diabetes model. In this study, we conducted a 12-week, randomized, double-blinded, and placebo-controlled clinical trial to determine the effects of OSM in humans with hyperglycemia. Participants with fasting plasma concentrations of 100-140 mg/dL were enrolled (

Indexed as

Diabetes Mellitus, Type 2HyperglycemiaSchisandraBlood GlucoseDouble-Blind MethodFructosamineGlycated HemoglobinHumansHypoglycemic AgentsInsulinBlood GlucoseFructosamineGlycated HemoglobinHypoglycemic AgentsInsulinclinical trialglycemic controlOmijaOmija extract mixtureSchisandra chinensissoybeantype 2 diabetes

Identifiers

PMID35956334
PMCPMC9370295
OpenAlexW4289204547

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.